Supplementary Table S1. Prescribed drugs in real-world in South Korea

Variable	Total patients (n=3,477)	Patients before 2019 (2005–2018) (n=2,534)	Patients after 2019 (2019–2022) (n=943)	p-value
Any drug of followings	2,975 (85.6)	2,135 (84.3)	840 (89.1)	<0.001*
Any inhaler of followings	2,838 (81.6)	2,040 (80.5)	798 (84.6)	0.005*
ICS	9 (0.3)	5 (0.2)	4 (0.4)	0.265
LABA	169 (4.9)	156 (6.2)	13 (1.4)	<0.001*
LAMA	620 (17.8)	543 (21.4)	77 (8.2)	<0.001*
LABA/LAMA	760 (21.9)	291 (11.5)	469 (49.7)	<0.001*
ICS/LABA	378 (10.9)	307 (12.1)	71 (7.5)	<0.001*
ICS/LABA/LAMA (SITT+MITT)	642 (18.5)	551 (21.7)	91 (9.7)	<0.001*
Methylxanthine without inhaler	101 (2.9)	92 (3.2)	9 (1.0)	<0.001*
PDE4 inhibitor without inhaler	15 (0.4)	14 (0.6)	1 (0.1)	0.085

Values are presented as number (%).
*p<0.05.
ICS: inhaled corticosteroid; LABA: long-acting beta 2 agonist; LAMA: long-acting muscarinic antagonist; SITT: single inhaler triple therapy; MITT: multiple inhaler triple therapy; PDE4: phosphodiesterase-4.